Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients

Blood Cancer Journal

Volumn 6, Issue 2, 2016, Pages

  Kortuem, K M ^a   Braggio, E ^a   Bruins, L ^a   Barrio, S ^a   Shi, C S ^a   Zhu, Y X ^a   Tibes, R ^a   Viswanatha, D ^b   Votruba, P ^a   Ahmann, G ^a   Fonseca, R ^a   Jedlowski, P ^a   Schlam, I ^a   Kumar, S ^b   Bergsagel, P L ^a   Stewart, A K ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; INTERFERON REGULATORY FACTOR 4; K RAS PROTEIN; LENALIDOMIDE; PROTEIN P53; STAT3 PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; ANTINEOPLASTIC AGENT;

ACTG GENE; ADULT; ARTICLE; ATM GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CCND1 GENE; CODON; COHORT ANALYSIS; COPY NUMBER VARIATION; CYLD GENE; DIS3 GENE; DRUG RESPONSE; FAM46C GENE; GENE; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; KRAS GENE; MAJOR CLINICAL STUDY; MAX GENE; MULTIPLE MYELOMA; ONCOGENE N RAS; PREDICTIVE VALUE; SEQUENCE ANALYSIS; SP140 GENE; TNFRSF21 GENE; AGED; CLONAL EVOLUTION; DNA MUTATIONAL ANALYSIS; DRUG EFFECTS; FOLLOW UP; GENETIC HETEROGENEITY; GENETICS; HIGH THROUGHPUT SEQUENCING; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; PROGNOSIS; SIGNAL TRANSDUCTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CLONAL EVOLUTION; DNA COPY NUMBER VARIATIONS; DNA MUTATIONAL ANALYSIS; FOLLOW-UP STUDIES; GENETIC HETEROGENEITY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; MUTATION; PROGNOSIS; SIGNAL TRANSDUCTION;

EID: 85016505124     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2016.1     Document Type: Article

References (24)

1. Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun 2014; 5: 2997.
2. Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM et al. Mutational spectrum, copy number changes, and outcome: Results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol 2015; 33: 3911-3920.
3. Lonial S, Yellapantula VD, Liang W, Kurdoglu A, Aldrich J, Legendre CM et al. Interim Analysis of the Mmrf Commpass Trial: Identification of Novel Rearrangements Potentially Associated with Disease Initiation and Progression 2014, ASH Meeting abstracts, 06 December 2014, p 722.
4. Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D et al. Widespread genetic heterogeneity in multiple myeloma: Implications for targeted therapy. Cancer Cell 2014; 25: 91-101.
5. Brioli A, Melchor L, Cavo M, Morgan GJ. The impact of intra-clonal heterogeneity on the treatment of multiple myeloma. Br J Haematol 2014; 165: 441-454.
6. Melchor L, Brioli A, Wardell CP, Murison A, Potter NE, Kaiser MF et al. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia 2014; 28: 1705-1715.
7. Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E et al. Clonal competition with alternating dominance in multiple myeloma. Blood 2012; 120: 1067-1076.
8. Egan JB, Shi CX, Tembe W, Christoforides A, Kurdoglu A, Sinari S et al. Wholegenome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 2012; 120: 1060-1066.
9. Kortum KM, Langer C, Monge J, Bruins L, Egan JB, Zhu YX et al. Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease. Br J Haematol 2015; 168: 507-510.
10. Kortum KM, Langer C, Monge J, Bruins L, Zhu YX, Shi CX et al. Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P). Ann Hematol 2015; 94: 1205-1211.
11. Kocher JP, Quest DJ, Duffy P, Meiners MA, Moore RM, Rider D et al. The Biological Reference Repository (BioR): A rapid and flexible system for genomics annotation. Bioinformatics 2014; 30: 1920-1922.
12. Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmaki H, Andersson EI et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012; 366: 1905-1913.
13. Huang X, Meng B, Iqbal J, Ding BB, Perry AM, Cao W et al. Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2013; 31: 4520-4528.
14. Wu ZL, Song YQ, Shi YF, Zhu J. High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma. J Hematol Oncol 2011; 4: 31.
15. Qiu ZY, Fan L, Wang L, Qiao C, Wu YJ, Zhou JF et al. STAT3 mutations are frequent in T-cell large granular lymphocytic leukemia with pure red cell aplasia. J Hematol Oncol 2013; 6: 82.
16. Raab MS, Xu J, Hielscher T, Lehners N, Ellert E, Ho AD et al. Signaling Pathway Profiling in Multiple Myeloma 2014, ASH Meeting abstracts, 06 December 2014, p 644.
17. Flanagan SE, Haapaniemi E, Russell MA, Caswell R, Lango Allen H, De Franco E et al. Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nat Genet 2014; 46: 812-814.
18. Ohgami RS, Ma L, Monabati A, Zehnder JL, Arber DA. STAT3 mutations are present in aggressive B-cell lymphomas including a subset of diffuse large B-cell lymphomas with CD30 expression. Haematologica 2014; 99: E105-e107.
19. Couronne L, Scourzic L, Pilati C, Della Valle V, Duffourd Y, Solary E et al. STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. Haematologica 2013; 98: 1748-1752.
20. Kucuk C, Jiang B, Hu X, Zhang W, Chan JK, Xiao W et al. Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells. Nat Commun 2015; 6: 6025.
21. Pilati C, Amessou M, Bihl MP, Balabaud C, Nhieu JT, Paradis V et al. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J Exp Med 2011; 208: 1359-1366.
22. Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci USA 2012; 109: 3879-3884.
23. Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood 2014; 123: 1293-1296.
24. Hu G, Witzig TE, Gupta M. A novel missense (M206K) STAT3 mutation in diffuse large B cell lymphoma deregulates STAT3 signaling. PloS One 2013; 8: E67851.